{"id":52463,"title":"Bevacizumab and relapsed ovarian cancer: too many serious and life-threatening adverse effects.","abstract":"No proven increase in overall survival when bevacizumab is added to carboplatin and gemcitabine, but significant, sometimes fatal additional adverse effects.","date":"2014-03-06","categories":"Endocrine System Diseases","split":"train","url":"http://www.ncbi.nlm.nih.gov/pubmed/24600726","annotations":[{"name":"Carboplatin","weight":0.913439,"wikipedia_article":"http://en.wikipedia.org/wiki/Carboplatin"},{"name":"Bevacizumab","weight":0.906012,"wikipedia_article":"http://en.wikipedia.org/wiki/Bevacizumab"},{"name":"Gemcitabine","weight":0.889412,"wikipedia_article":"http://en.wikipedia.org/wiki/Gemcitabine"},{"name":"Ovarian cancer","weight":0.882315,"wikipedia_article":"http://en.wikipedia.org/wiki/Ovarian_cancer"},{"name":"Cancer","weight":0.781843,"wikipedia_article":"http://en.wikipedia.org/wiki/Cancer"},{"name":"Adverse effect","weight":0.626563,"wikipedia_article":"http://en.wikipedia.org/wiki/Adverse_effect"},{"name":"Survival rate","weight":0.0923993,"wikipedia_article":"http://en.wikipedia.org/wiki/Survival_rate"}]}
